Royal DSM repurchased 204,254 of its own shares to cover existing option plans

HEERLEN, 3-8-2015 — /EuropaWire/ — Royal DSM, the global Life Sciences and Materials Sciences company, has repurchased 204,254 of its own shares in the period from 24 July 2015 up to and including 28 July 2015 at an average price of €52.44. This is in accordance with the repurchase, covering existing option plans, announced on 14 May 2015. The consideration of this repurchase was €10.7 million.

This repurchase concludes the program to repurchase 2,300,000 shares for a total consideration of €122.5 million.

DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

For more information:
DSM Corporate Communications
Herman Betten
tel. +31 (0) 45 5782017
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
e-mail investor.relations@dsm.com

Forward-looking statements This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

EDITOR'S PICK:

EuropaWire PR Editors

Recent Posts

Eurojust Symposium Advocates for Enhanced Protection of Crime Victims Across Europe

(IN BRIEF) Eurojust recently hosted a landmark symposium in collaboration with the Belgian Presidency of…

32 mins ago

Evotec Biologics Unveils J.CHO™ High Expression System for Enhanced Antibody Production

(IN BRIEF) Evotec Biologics, the biologics arm of Evotec SE, has introduced its proprietary J.CHO™…

20 hours ago

CVC Capital Partners plc Successfully Lists on Euronext Amsterdam

(IN BRIEF) Euronext extends congratulations to CVC Capital Partners plc (CVC) for its triumphant listing…

20 hours ago